Explore 3 Stock Ideas & Industry Insights Download Free Report

Healthcare

What Did BridgeBio's (NASDAQ:BBIO) Encaleret Show in Phase 3?

The October 12, 2026 report asked whether Biohaven's encaleret succeeded in Phase 3 for a rare calcium-regulation disorder. Company materials show that encaleret is developed by BridgeBio Pharma (NASDAQ:BBIO), not by Biohaven, so the attribution appears wrong. The drug targets autosomal dominant hypocalcemia type …

Vinay Lochav | 13 October 2026

Why Did Biogen (NASDAQ:BIIB) Rise 4% After a JPMorgan Upgrade?

JPMorgan raised its rating on Biogen (NASDAQ:BIIB) to Overweight on October 12, 2026, and the shares rose about 4% early, according to published market data. Overweight means the analyst expects the stock to outperform comparable companies over the coming year, which is an opinion …

Vinay Lochav | 13 October 2026

What Are This Week's Biotech Catalysts for SPDR (NYSEARCA:XBI)?

The biotech calendar for October 12 to 20, 2026 includes Edgewise Therapeutics data at the Heart Failure Society of America meeting on October 12, an Arrowhead Pharmaceuticals webinar on ARO-MAPT on October 14 at 11:30 a.m. PT, and a Regenxbio sura-vec event on October …

Vinay Lochav | 13 October 2026

Why Did Merck (NYSE:MRK), Bristol Myers (NYSE:BMY), Contineum (NASDAQ:CTNM) and BridgeBio (NASDAQ:BBIO) Move on Trial Data?

Merck (NYSE:MRK) presented one-year results for remigromig in diabetic macular edema, a swelling of the central retina caused by leaking vessels in people with diabetes. Vision improved by 9.1 and 8.7 letters in two groups compared with 11.8 letters for ranibizumab, the established injection …

Vinay Lochav | 13 October 2026

What Are the Biotech Catalysts This Week for Edgewise (NASDAQ:EWTX), Arrowhead (NASDAQ:ARWR), Regenxbio (NASDAQ:RGNX) and First Tracks (NASDAQ:TRAX)?

Edgewise Therapeutics (NASDAQ:EWTX) presented data at the Heart Failure Society of America meeting on October 12, 2026, according to company event notices. The topic of the presentation was not captured in published information, so this article does not describe results or the program involved. …

Vinay Lochav | 13 October 2026

Why Did Medtronic (NYSE:MDT), Zimmer Biomet (NYSE:ZBH), Insulet (NASDAQ:PODD) and GE HealthCare Technologies (NASDAQ:GEHC) Rise Up to 3.9%?

Medtronic (NYSE:MDT) rose 3.9% on October 12, 2026, the largest advance among five medical technology names. The company makes devices for heart, spine, surgical and diabetes care, and sells them to hospitals worldwide, so its revenue depends on procedure volumes and hospital budgets. No …

Vinay Lochav | 13 October 2026

Why Did STERIS (NYSE:STE) Pay USD 2.1 Billion and Rise 2.8%?

STERIS (NYSE:STE) supplies infection prevention and surgical products to hospitals, and it agreed on October 12, 2026 to pay USD 2.1 billion for Xodus Medical. The company announcement describes a tax benefit of about USD 300 million, which lowers the net cost to about …

Vinay Lochav | 13 October 2026

Why Did Medtronic (NYSE:MDT) Lead a 3.9% Medtech Rally?

Medtronic (NYSE:MDT) gained 3.9% in the October 12, 2026 session, according to published market data, and four peers also rose. Zimmer Biomet (NYSE:ZBH) added 3.4%. Insulet (NASDAQ:PODD) added 3.3%. GE HealthCare Technologies (NASDAQ:GEHC) gained 3.0%. Becton Dickinson (NYSE:BDX) gained 2.8%, so the five names …

Vinay Lochav | 13 October 2026

Why Does UnitedHealth (NYSE:UNH) Face a USD 4.12 EPS Test Today?

Per published estimates, UnitedHealth Group (NYSE:UNH) is expected to report earnings per share of USD 4.12 on revenue of about USD 111.3 billion for the quarter. Both figures appear in two separate estimate sets, which makes them more reliable than most single figures. Consensus …

Vinay Lochav | 13 October 2026

Why Do Johnson & Johnson (NYSE:JNJ) Results Test a USD 2.53 Bar?

Per published estimates, Johnson & Johnson (NYSE:JNJ) is expected to post earnings per share of USD 2.53 to USD 2.54 on revenue of about USD 25.4 billion. The one-cent gap reflects the use of different providers, so the article uses the range. The company …

Vinay Lochav | 13 October 2026
Support

Hi! How can we help you today?

Loading…